Neuronal Signaling

PDMP hydrochloride is a potent inhibitor of glucosylceramide synthase (GCS). This compound has been shown to induce apoptosis in K562/A02 cells, making it a valuable tool for studying cancer biology, particularly in leukemia research. PDMP hydrochloride's ability to disrupt glycosphingolipid metabolism provides insights into therapeutic strategies targeting GCS in cancer treatment.

SC-236 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 10 nM and also acts as a PPARγ agonist. It effectively suppresses activator protein-1 (AP-1) through the inhibition of c-Jun NH2-terminal kinase, demonstrating significant anti-inflammatory effects. SC-236 has been shown to reduce ERK phosphorylation in murine models, highlighting its potential for investigating inflammatory pathways and therapeutic interventions.

Humulone, a prenylated phloroglucinol derivative, is a selective inhibitor of cyclooxygenase-2 (COX-2). It demonstrates significant anti-inflammatory properties and serves as a positive modulator of GABAA receptors at low micromolar concentrations. Additionally, Humulone is known to inhibit bone resorption and exhibits antioxidant, anti-angiogenic, and pro-apoptotic activities, making it valuable for various research applications in inflammation and cancer studies.

DuP-697 is a potent, irreversible, and selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 10 nM for human COX-2 and 800 nM for COX-1. This compound demonstrates significant antiproliferative effects on HT29 colorectal cancer cells with an IC50 of 42.8 nM, as well as antiangiogenic and pro-apoptotic activities. By inhibiting prostaglandin synthesis, DuP-697 offers potential applications in studies related to inflammation, cancer, and fever reduction.

Dimethoate is an organophosphate insecticide and acaricide that functions primarily as an acetylcholinesterase inhibitor. It exhibits significant biological activity by inducing reactive oxygen species (ROS) production, leading to DNA damage and apoptosis in vivo. Additionally, Dimethoate impacts the immune system in murine models, highlighting its relevance in toxicological and environmental research applications.

α-Thujone is a monoterpene that acts as a reversible modulator of the GABA type A receptor, with an IC50 of 21 μM for inhibiting GABA-induced currents. This compound demonstrates significant anti-tumor activity by inducing reactive oxygen species (ROS) accumulation, as well as promoting cell apoptosis and autophagy. Additionally, α-Thujone exhibits antinociceptive, insecticidal, and anthelmintic properties, while being capable of crossing the blood-brain barrier, making it valuable for various biological research applications.

Metamizole sodium is a potent cyclooxygenase (COX) inhibitor that exhibits significant anti-inflammatory, analgesic, and antipyretic properties. This compound not only inhibits cell proliferation but also promotes apoptosis in various cell types. Additionally, Metamizole sodium serves as a spasmolytic agent, making it a valuable tool for research applications aimed at pain relief and the study of inflammatory processes. Its multifunctional activities contribute to its utility in diverse areas of biomedical research.

β-NETA is a potent noncompetitive inhibitor of cholinesterase (ChE) and choline acetyltransferase (ChA), with IC50 values of 40 μM and 76 μM, respectively. Additionally, it exhibits weak inhibitory effects on acetylcholinesterase (AChE), with an IC50 value of 1 mM. This compound is relevant for research in neurobiology and studies focused on cholinergic signaling pathways and associated disorders.

Gypsogenin is a selective mixed-type inhibitor of butyrylcholinesterase (BChE) with a Ki of 19.99 μM. It demonstrates significant cytotoxicity against multiple human cancer cell lines by inducing cell cycle arrest and initiating apoptosis. Additionally, Gypsogenin exhibits antibacterial properties against species such as Bacillus subtilis and Bacillus thuringiensis, positioning it as a crucial scaffold for developing novel anticancer agents. This compound is extensively utilized in research focusing on Alzheimer's disease and various cancers, including colon cancer, melanoma, and leukemia.

α7 nAchR-JAK2-STAT3 agonist 1 is a selective agonist targeting the α7 nicotinic acetylcholine receptor, modulating the JAK2-STAT3 signaling pathway. It demonstrates significant anti-inflammatory activity by inhibiting the expression of inducible nitric oxide synthase (iNOS), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) in murine RAW264.7 macrophages, with an IC50 of 0.32 μM for nitric oxide production. Additionally, it effectively suppresses lipopolysaccharide (LPS)-induced nitric oxide release, NF-κB activation, and related cytokine production. This compound is valuable for studying sepsis and inflammatory responses.

FMF-06-098-1 is a multitargeted kinase PROTAC degrader designed to promote the degradation of various kinases, including AAK1, ABL2, AURKA, and WEE1, among others. This compound exhibits broad biological activity by modulating kinase levels, which can influence cellular signaling pathways and impact cancer progression. FMF-06-098-1 is valuable in research applications focused on understanding kinase function and developing therapeutic strategies targeting multiple kinases in various diseases.

Galanthamine-d6 is a deuterium-labeled derivative of Galanthamine, a potent inhibitor of acetylcholinesterase (AChE) with an IC50 value of 500 nM. This stable isotope compound is valuable in pharmacokinetic studies and metabolic research, particularly in exploring the mechanisms of cholinergic modulation. Its isotopic labeling helps in the precise tracking of metabolite pathways in biological assays.

Cardanol monoene is a phenolic compound derived from cashew nut shell liquid, primarily targeting cellular mechanisms involved in cancer progression. It exhibits significant anti-cancer activities, including the inhibition of cell proliferation and migration, S phase arrest, and induction of apoptosis via reactive oxygen species (ROS) production and mitochondrial depolarization. Cardanol monoene modulates key signaling pathways by downregulating MMP-2 and MMP-9 expressions and regulating the expression of CDK2, p53, and Bax, among others. Additionally, it demonstrates weak DPPH radical scavenging and acetylcholinesterase inhibition activities, making it suitable for research in cancer, infection, and inflammation.

Tolcapone-d4 is a deuterated derivative of the selective catechol-O-methyltransferase (COMT) inhibitor, Tolcapone. This compound exhibits an IC50 of 773 nM, demonstrating its potency in inhibiting COMT activity. Tolcapone-d4 is utilized in research related to neurodegenerative disorders and cancer, as it influences α-synuclein and amyloid-beta oligomerization and fibrillogenesis. Additionally, it has been shown to induce oxidative stress, promote apoptosis in cancer cells, and increase reactive oxygen species (ROS) production, making it valuable for studies in both cancer and neurological disease contexts.

Kokusaginine is a furoquinoline alkaloid that acts as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 28.2 μM. This compound has demonstrated anti-proliferative and apoptotic effects in MCF-7/ADR cancer cell lines, making it a valuable reagent for research in neurobiology and cancer biology. Its ability to modulate cholinergic signaling and induce cell death highlights its potential for further investigation in therapeutic applications.

ZLMT-12 is a potent CDK2/9 inhibitor, demonstrating IC50 values of 0.002 μM and 0.011 μM against CDK9 and CDK2, respectively. This compound is derived from tacrine and exhibits weak inhibition of acetylcholinesterase (IC50 = 19.023 μM) and butyrylcholinesterase (IC50 = 2.768 μM). ZLMT-12 is characterized by low toxicity and notable antiproliferative activity, effectively inducing apoptosis and facilitating cell cycle arrest in the S and G2/M phases. This compound serves as a valuable tool for research in cell cycle regulation and therapeutic development in cancer biology.

Ketorolac hemicalcium is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective cyclooxygenase (COX) inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in research related to allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain, as well as for its potential applications in cancer research due to its role as a DDX3 inhibitor.

Metamizole magnesium is an orally active cyclooxygenase (COX) inhibitor known for its key roles in reducing inflammation and pain. It exhibits significant anti-inflammatory and antioxidant activities, along with the ability to inhibit cell proliferation and promote apoptosis. Due to its antipyretic and analgesic properties, Metamizole magnesium is commonly utilized in various research applications aimed at investigating pain mechanisms and inflammatory responses.

Topo I/COX-2-IN-1 is an inhibitor of both Topoisomerase I and Cyclooxygenase-2 (COX-2). It demonstrates significant biological activity, with IC50 values of 0.24 μM for COX-2 and 4.42 μM for Topo I. This compound effectively induces apoptosis and inhibits the migration of cancer cells, showcasing potential applications in cancer research and therapy.

Topo I/COX-2-IN-2 is a potent dual-target inhibitor of Topoisomerase I (Topo I) and Cyclooxygenase-2 (COX-2), exhibiting inhibitory concentrations (IC50) of 0.90 μM and 2.31 μM, respectively. This compound induces apoptosis in cancer cells via the mitochondrial pathway, making it a valuable agent for research in cancer therapeutics and cell death mechanisms. Its dual activity supports investigations into the interplay between topoisomerase inhibition and inflammatory pathways in cancer progression.

3-O-Methyltolcapone is a drug metabolite derived from Tolcapone, a selective and potent inhibitor of catechol-O-methyltransferase (COMT) with an IC50 of 773 nM. This compound is known to block α-synuclein and Aβ42 oligomerization and fibrillogenesis, while also inducing oxidative stress, apoptosis in cancer cells, and reactive oxygen species (ROS) production. Research applications include studies related to cancer and neurological disorders, particularly in the context of Parkinson’s disease and neuroblastoma.

OSU-03013 is a Celecoxib analog that targets multiple pathways involved in cancer progression. It promotes apoptosis while enhancing E-cadherin expression and reduces β-catenin, c-myc, Wnt1, and N-cadherin levels. By inhibiting cell migration and invasion, OSU-03013 effectively regulates Wnt and mTOR signaling, leading to decreased proliferation of colon cancer cells. This compound is suitable for research focused on colon cancer and its underlying mechanisms.

α-NETA is a potent noncompetitive inhibitor of choline acetyltransferase (ChA), exhibiting an IC50 value of 9 μM. Additionally, it displays strong antagonistic activity against aldehyde dehydrogenase 1A1 (ALDH1A1) with an IC50 of 0.04 µM and also targets chemokine-like receptor-1 (CMKLR1). While it shows some inhibitory effects on cholinesterase (ChE) and acetylcholinesterase (AChE) with higher IC50 values, α-NETA is notable for its anti-cancer properties, making it a valuable tool for research in cancer biology and neuropharmacology.

Ibuprofen sodium is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 13 μM. This compound demonstrates significant biological activities, including inhibition of cell proliferation, angiogenesis, and induction of apoptosis. As a nonsteroidal anti-inflammatory agent and nitric oxide (NO) donor, ibuprofen sodium is valuable in research areas such as pain, inflammation, infection, immunology, and oncology.

Nirogacestat dihydrobromide is a selective, noncompetitive inhibitor of γ-secretase, with a reported IC50 of 6.2 nM. This compound effectively inhibits Notch signaling, making it a valuable tool for studying Notch receptor-dependent cancers while minimizing gastrointestinal toxicity. It is particularly useful in research focused on the role of γ-secretase in cancer biology and therapeutic development.

Cipepofol is a positive allosteric modulator and direct agonist of the GABAA receptor. This compound demonstrates significant central nervous system inhibition and promotes sleep, offering potential applications in anesthesia and sleep research. Additionally, Cipepofol activates the Sirtuin1 (Sirt1)/Nrf2 pathway, providing cardioprotective effects against isoproterenol-induced myocardial infarction by reducing oxidative stress, inflammatory responses, and cardiomyocyte apoptosis.

Pyridoxal 5′-phosphate monohydrate is the active coenzyme form of vitamin B6 and is essential for the function of numerous enzymes. It serves as a key cofactor for aromatic L-amino acid decarboxylase, which catalyzes the final step in the biosynthesis of the neurotransmitters dopamine and serotonin. Pyridoxal 5′-phosphate is the primary intracellular phosphorylated form of vitamin B6 and is interconvertible with other forms, including pyridoxine 5′-phosphate (PNP) and pyridoxamine 5′-phosphate (PMP).

Isofraxidin is a coumarin compound derived from *Acanthopanax senticosus* that exhibits anti-invasive and anti-inflammatory properties. It inhibits MMP-7 expression and suppresses cell invasion in human hepatoma cells by reducing ERK1/2 phosphorylation. Isofraxidin also downregulates the expression of iNOS and COX-2 and inhibits the formation of the TLR4/myeloid differentiation protein-2 (MD-2) complex.

Phenidone is an orally active dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX) pathways, exhibiting anti-inflammatory and immunomodulatory effects. It has been shown to ameliorate paralysis in rat models of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. Phenidone also acts as a potent hypotensive agent in spontaneously hypertensive rats. Additionally, it has a long-standing application as a photographic developer due to its redox properties.

Glafenine is a non-selective, non-steroidal anti-inflammatory drug (NSAID) that inhibits both COX-1 and COX-2 enzymes. It exerts anti-inflammatory, anti-proliferative, and anti-migratory effects by suppressing the arachidonic acid metabolic pathway, thereby reducing prostaglandin production. Additionally, glafenine induces cell cycle arrest in vascular smooth muscle cells and endothelial cells and decreases the synthesis of the extracellular matrix protein tenascin. It is utilized in research related to inflammatory disorders, vascular restenosis, and cystic fibrosis.

Picfeltarraenin IA is a triterpenoid compound isolated from *Picria fel-terrae* (*P. fel-terrae*) that functions as an acetylcholinesterase (AChE) inhibitor. It exhibits therapeutic potential for the treatment of herpes infections, cancer, and inflammatory conditions, making it a promising candidate for further pharmacological research.

Dexketoprofen trometamol (Dexketoprofen tromethamine salt) is an orally active, non-selective cyclooxygenase (COX) inhibitor. It exhibits analgesic, anti-inflammatory, and anti-cancer effects. As the active enantiomer of ketoprofen, Dexketoprofen trometamol is commonly used for the management of pain and inflammation, and it is also under investigation for its potential anticancer properties.

SC-58125 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 0.04 μM. It demonstrates antitumor activity both in vitro and in vivo and is effective in reducing inflammation-related edema. Additionally, SC-58125 possesses analgesic properties, making it a valuable compound for research in cancer, inflammation, and pain management.

Lobeglitazone sulfate is a novel thiazolidinedione and an orally active agonist of peroxisome proliferator-activated receptors (PPARs), with EC50 values of 137.4 nM for PPARγ and 546.3 nM for PPARα. It also acts as an inhibitor of the ERK/JNK/Smad/NF-κB signaling pathways. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic activities, supporting its potential in the treatment of metabolic and inflammatory diseases.

7-Hydroxyflavone is an orally active flavonoid isolated from *Clerodendrum phlomidis*, exhibiting notable anti-inflammatory activity. It protects renal cells from nicotine-induced cytotoxicity through activation of the ERK/Nrf2/HO-1 signaling pathway. Additionally, 7-Hydroxyflavone inhibits PKM2 with an IC50 of 2.12 μM, and suppresses COX-2 and 5-LOX with IC50 values of 27 μg/mL and 33 μg/mL, respectively.

α-Amyrin is an orally active pentacyclic triterpenoid that activates the ERK and GSK-3β signaling pathways. It is studied for its potential in treating metabolic syndrome induced by a high-fructose diet and cognitive dysfunction associated with reduced cholinergic neurotransmission.

Fenoprofen (LILLY-53858) is a nonsteroidal anti-inflammatory drug (NSAID) that functions primarily by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of pro-inflammatory prostaglandins. In addition to its classical NSAID activity, Fenoprofen has been identified as a positive allosteric modulator (PAM) of melanocortin receptors (MCRs), enhancing MCR-mediated signaling. Fenoprofen also promotes ERK1/2 activation in HEK293T cells, suggesting additional modulation of intracellular signaling pathways involved in inflammation and cellular proliferation.

Pyridoxal 5′-phosphate hydrate (PLP) is the biologically active form of vitamin B6 and serves as an essential cofactor for over 100 enzymatic reactions, particularly those involved in amino acid metabolism. It plays a critical role in the function of aromatic L-amino acid decarboxylase, the enzyme responsible for catalyzing the final step in the synthesis of key neurotransmitters such as dopamine and serotonin. PLP is the principal coenzyme form generated through intracellular phosphorylation of vitamin B6 precursors and is interconvertible with other phosphorylated forms, including pyridoxine 5′-phosphate (PNP) and pyridoxamine 5′-phosphate (PMP).

Penehyclidine hydrochloride (also known as Penequinine hydrochloride) is a selective anticholinergic agent that acts as an antagonist of muscarinic M1 and M3 receptors. It exerts anti-inflammatory effects by modulating immune signaling in lung tissue, notably through activation of the NF-κB pathway and inhibition of pro-inflammatory cytokine release. In preclinical studies, Penehyclidine hydrochloride has been shown to alleviate pulmonary inflammation in rat models of chronic obstructive pulmonary disease (COPD), particularly under conditions of mechanical ventilation. These properties suggest its potential utility in managing respiratory inflammatory conditions and improving outcomes in mechanically ventilated patients with COPD.

Lobeglitazone is a novel thiazolidinedione-class compound and an orally active dual agonist of peroxisome proliferator-activated receptors (PPARs), with EC₅₀ values of 137.4 nM for PPARγ and 546.3 nM for PPARα. In addition to its metabolic effects, Lobeglitazone functions as an inhibitor of multiple pro-inflammatory and pro-fibrotic signaling pathways, including ERK, JNK, Smad, and NF-κB. Lobeglitazone exhibits a broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic effects. These properties make it a promising candidate for therapeutic research in metabolic syndrome, type 2 diabetes, cardiovascular disease, and fibrosis-related conditions.

MAPK-IN-1 (Compound 2) is an inhibitor of the MAPK signaling pathway with demonstrated neuroprotective and anti-neuroinflammatory properties. It also exhibits acetylcholinesterase (AChE) inhibitory activity, with an IC₅₀ of 23.84 μM, contributing to enhanced cholinergic signaling. These combined actions make MAPK-IN-1 a promising candidate for research in Alzheimer's disease and other neurodegenerative disorders, where modulation of MAPK signaling and cholinergic function are of therapeutic interest.

6-Hydroxyflavone is an orally active flavonoid with diverse pharmacological properties. It exhibits anti-inflammatory activity by inhibiting lipopolysaccharide (LPS)-induced nitric oxide (NO) production and also promotes osteoblast differentiation through activation of the AKT, ERK1/2, and JNK signaling pathways, supporting its role in bone health. Additionally, 6-Hydroxyflavone inhibits the glycosylation of bovine hemoglobin (BHb), suggesting potential in managing glycation-related complications. It demonstrates kidney-protective effects and modulates GABAergic neurotransmission by enhancing GABA-induced currents via the benzodiazepine binding sites on GABAA receptors

CLH304a (compound 14) is a selective and noncompetitive negative allosteric modulator (NAM) of the GABA$_B$ receptor. It specifically targets the heptahelical domain of the GB2 subunit, inhibiting receptor activity with inverse agonist properties. CLH304a reduces GABA-induced inositol trisphosphate (IP₃) production with an IC₅₀ of 37.9 μM and does not affect other Class C GPCRs, including mGluR1, mGluR2, and mGluR5, indicating high selectivity. Additionally, CLH304a inhibits Baclofen-induced ERK1/2 phosphorylation in HEK293 cells overexpressing GABA$_B$ receptors, further supporting its function as a negative modulator. This compound is a valuable tool for investigating GABA$_B$ receptor function and holds potential for therapeutic research in neurological disorders involving GABAergic signaling dysregulation.

Gnetol is a bioactive phenolic compound isolated from the root of *Gnetum montanum* with diverse pharmacological properties. It potently inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 0.78 μM and exhibits histone deacetylase (HDAC) inhibitory activity. Gnetol is also a strong tyrosinase inhibitor, with an IC₅₀ of 4.5 μM against murine tyrosinase, leading to suppression of melanin biosynthesis. In addition to its antioxidant, antiproliferative, anticancer, and hepatoprotective effects, Gnetol modulates metabolic enzymes in a concentration-dependent manner, including α-amylase, α-glucosidase, and adipogenesis pathways, making it a promising candidate for research in oncology, dermatology, and metabolic disorders.

AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3, also known as GPR41), with an IC₅₀ of 117 nM. It demonstrates anti-inflammatory, antitumor, and antidiabetic activities. AR420626 improves neurogenic diarrhea by modulating neural pathways mediated by nicotinic acetylcholine receptors (nAChRs). In cancer models, it suppresses the growth of HepG2 xenografts and inhibits hepatoma cell proliferation through apoptosis induction. Additionally, AR420626 mitigates allergic asthma and eczema and enhances glucose uptake by activating FFAR3-mediated Ca²⁺ signaling, offering potential therapeutic benefits in metabolic disorders such as diabetes.

QC-01-175 is a heterobifunctional PROTAC molecule designed to degrade aberrant tau protein. It effectively reduces levels of A152T and P301L mutant tau, mitigates tau-mediated neurotoxicity, and enhances neuronal survival.

Tau Peptide (306–317) is a synthetic polypeptide fragment identified through peptide screening, a research technique that pools and evaluates active peptides—primarily via immunoassays. Peptide screening is widely used for studying protein–protein interactions, functional analysis, and epitope mapping, making Tau Peptide (306–317) a valuable tool in the research and development of therapeutic agents, particularly in neurodegenerative disease studies.

The Italian mutation of β-amyloid 1-40 (E22K) exhibits faster aggregation kinetics and greater neurotoxicity compared to the wild-type peptide. Solid-state NMR studies (Masuda et al.) suggest this enhanced toxicity may be linked to the formation of a salt bridge between Lys²² and Asp²³ in a minor conformer. Similar to the Arctic, Flemish, and Dutch Aβ variants, the Italian mutant also shows significantly reduced degradation by the Aβ-cleaving enzyme neprilysin, contributing to its pathological accumulation.

Pregnanolone, also known as eltanolone, is an endogenous inhibitory neurosteroid that is produced in the body from progesterone.

Cudraflavone B is a prenylated flavonoid that functions as a dual inhibitor of COX-1 and COX-2, demonstrating significant anti-inflammatory and anti-tumor activity. This compound inhibits the translocation of nuclear factor κB (NF-κB) in macrophages, leading to decreased tumor necrosis factor α (TNFα) gene expression and secretion. Additionally, Cudraflavone B induces the mitochondrial apoptotic pathway while activating MAPK signaling pathways, including p38 and ERK, and upregulating SIRT1 expression. These mechanisms contribute to its efficacy in attenuating the growth of human oral squamous cell carcinoma cells, making it a valuable tool for cancer research.